ASTRO 2022 | Results of the Phase III PCS5 trial of hypofractionated radiotherapy for prostate cancer

Tamim Niazi, MD, McGill University, Montreal, Quebec, Canada, shares the 7-year outcomes of the Phase III PCS5 trial (NCT01444820) of dose escalation radiotherapy for high-risk prostate cancer patients. There was no difference between the treatment arms in terms of survival outcomes. Notably, survival in terms of biochemical recurrence was over 80%, and survival in terms of prostate cancer specific mortality was over 90%. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.